Mirum Pharmaceuticals (MIRM) Is Up 5.2% After Issuing Confident 2026 Revenue Outlook and Pipeline Update

Simply Wall St.01-19

Earlier this month, Mirum Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining its business outlook and pipeline plans to investors. The company ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604890438?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-19 08:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604890438","market":"nz","top_or_hot":-1,"title":"Mirum Pharmaceuticals (MIRM) Is Up 5.2% After Issuing Confident 2026 Revenue Outlook and Pipeline Update","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Mirum Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining its business outlook and pipeline plans to investors. The company ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals (MIRM) Is Up 5.2% After Issuing Confident 2026 Revenue Outlook and Pipeline Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals (MIRM) Is Up 5.2% After Issuing Confident 2026 Revenue Outlook and Pipeline Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-19 08:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Mirum Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining its business outlook and pipeline plans to investors. The company ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident","article_id":"2604890438","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604890438","pubTimestamp":1768782256,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Mirum Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining its business outlook and pipeline plans to investors.\nThe company underscored 2026 revenue guidance of US$630–US$650 million and highlighted several impending late-stage clinical readouts and intellectual property actions as key business drivers.\nNext, we'll examine how Mirum's confident 2026 revenue guidance and upcoming pivotal trial readouts could reshape...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc."},"translate_title":"Mirum Pharmaceuticals(MIRM)在发布充满信心的2026年收入展望和产品线更新后上涨5.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1.5},"content_text":"Earlier this month, Mirum Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining its business outlook and pipeline plans to investors. The company underscored 2026 revenue guidance of US$630–US$650 million and highlighted several impending late-stage clinical readouts and intellectual property actions as key business drivers. Next, we'll examine how Mirum's confident 2026 revenue guidance and upcoming pivotal trial readouts could reshape its broader investment narrative. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.AdvertisementMirum Pharmaceuticals Investment Narrative RecapTo own Mirum, you need to believe its rare liver disease franchise can keep expanding beyond Livmarli while late stage programs convert to commercial products. The J.P. Morgan update, with 2026 revenue guidance of US$630–US$650 million, reinforces revenue expectations and keeps upcoming pivotal data and patent outcomes as the key near term catalyst and the main risk around concentration in Livmarli. The most relevant update here is Mirum’s plan to pursue patent infringement lawsuits aimed at blocking generic versions of Livmarli, directly tied to protecting that 2026 revenue guidance. For investors who see Livmarli as the core cash generator that funds volixibat, brelovitug and earlier pipeline work, the outcome of these IP actions sits alongside trial readouts as a central driver of how durable the story could be. Yet while the growth story sounds appealing, investors should also be aware of how exposed Mirum remains if Livmarli faces unexpected competition or reimbursement pressure... Read the full narrative on Mirum Pharmaceuticals (it's free!)Mirum Pharmaceuticals' narrative projects $794.3 million revenue and $102.1 million earnings by 2028. This requires 22.8% yearly revenue growth and a $160.7 million earnings increase from -$58.6 million today.Uncover how Mirum Pharmaceuticals' forecasts yield a $103.10 fair value, a 13% upside to its current price.Exploring Other PerspectivesMIRM Earnings & Revenue Growth as at Jan 2026 Five fair value estimates from the Simply Wall St Community span roughly US$35 to over US$290 per share, with views scattered across that wide band. Against this backdrop, the company’s reliance on Livmarli as a primary revenue pillar raises important questions about how protected future cash flows really are and why it can be useful to compare several independent viewpoints before forming a view.Explore 5 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth over 3x more than the current price!Build Your Own Mirum Pharmaceuticals NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.Looking For Alternative Opportunities?Our top stock finds are flying under the radar-for now. Get in early:AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 38 best rare earth metal stocks of the very few that mine this essential strategic resource.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604890438","isCrawlerRequest":true}